HC Wainwright Has Weak Outlook for AngioDynamics Q1 Earnings

AngioDynamics, Inc. (NASDAQ:ANGO) – Analysts at HC Wainwright dropped their Q1 2026 earnings per share estimates for shares of AngioDynamics in a research note issued to investors on Wednesday, July 16th. HC Wainwright analyst Y. Chen now anticipates that the medical instruments supplier will earn ($0.14) per share for the quarter, down from their prior estimate of ($0.12). HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for AngioDynamics’ current full-year earnings is ($0.37) per share. HC Wainwright also issued estimates for AngioDynamics’ Q2 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at $0.02 EPS and FY2026 earnings at ($0.30) EPS.

AngioDynamics (NASDAQ:ANGO) last posted its earnings results on Tuesday, July 15th. The medical instruments supplier reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.09. AngioDynamics had a negative return on equity of 3.20% and a negative net margin of 11.62%. The firm had revenue of $80.16 million for the quarter, compared to the consensus estimate of $74.26 million. During the same quarter in the prior year, the business earned ($0.06) EPS. The business’s revenue for the quarter was up 13.0% on a year-over-year basis.

A number of other brokerages have also recently commented on ANGO. Canaccord Genuity Group set a $17.00 target price on AngioDynamics and gave the stock a “buy” rating in a report on Wednesday. Lake Street Capital began coverage on AngioDynamics in a report on Wednesday. They set a “buy” rating and a $24.00 price target on the stock.

AngioDynamics Stock Down 0.6%

AngioDynamics stock opened at $8.69 on Friday. The company has a market capitalization of $352.90 million, a P/E ratio of -10.47 and a beta of 0.60. The stock’s 50 day moving average is $9.86 and its 200 day moving average is $10.06. AngioDynamics has a twelve month low of $5.83 and a twelve month high of $13.50.

Institutional Investors Weigh In On AngioDynamics

A number of large investors have recently made changes to their positions in ANGO. Quinn Opportunity Partners LLC acquired a new position in shares of AngioDynamics during the 4th quarter worth about $92,000. ProShare Advisors LLC acquired a new position in shares of AngioDynamics during the 4th quarter worth about $100,000. Graham Capital Management L.P. acquired a new position in shares of AngioDynamics during the 4th quarter worth about $106,000. OneDigital Investment Advisors LLC raised its position in shares of AngioDynamics by 14.0% during the 4th quarter. OneDigital Investment Advisors LLC now owns 12,137 shares of the medical instruments supplier’s stock worth $111,000 after purchasing an additional 1,490 shares during the last quarter. Finally, Cerity Partners LLC raised its position in shares of AngioDynamics by 22.0% during the 1st quarter. Cerity Partners LLC now owns 12,929 shares of the medical instruments supplier’s stock worth $121,000 after purchasing an additional 2,333 shares during the last quarter. 89.43% of the stock is owned by hedge funds and other institutional investors.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.